Bing Lim, MD, PhD
Head of Cell Therapy
Bing Lim, MD, PhD, is the Head of Cell Therapy at Sana Biotechnology.
Most recently, he served as an Associate Vice President at Merck. Prior to that, he led a stem cell research laboratory for over 25 years, first as an Associate Professor at Beth Israel Deaconess Medical Center and Harvard Medical School, and subsequently, at the Genome Institute of Singapore as a Senior Group Leader and Associate Director.
Bing’s laboratory developed new methods to differentiate embryonic stem cells into desired cell types and has contributed to knowledge of the unique transcription factors at the heart of embryonic stem cell identity as well as induced pluripotent stem cell reprogramming. Most recently, his group discovered metabolic vulnerabilities of human cancer stem cells, suggesting future means to therapeutically target these cells.
Bing earned his MD from the University of Western Ontario and his PhD from the University of Toronto.